Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats

P. E. Binkerd, J. M. Rowland, H. Nau, Andrew G Hendrickx

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

This study was undertaken to assess the pharmacokinetics and developmental toxicity of the anticonvulsant, valproic acid (VPA), a human teratogen, in Sprague-Dawley rats. Oral administration of 200-800 mg/kg VPA (5-20 × human therapeutic dose) from Gestational Days (GD) 8 to 17 resulted in increasing maternal toxicity at the higher doses with 100% maternal lethality at 800 mg/kg. Although there was an increased incidence of resorptions at 600 mg/kg (48 ± 43%) compared to controls (18 ± 24%), it was not statistically significant. Fetal examination on GD 20 revealed dose-dependent fetal growth retardation (p ≤0.05) as evidenced by decreased fetal weight and length in addition to underossification of both the axial and appendicular skeleton. The incidence of skeletal defects, including abnormal vertebrae, ribs, and craniofacial dysmorphia, also increased with higher doses of VPA. Cardiac anomalies observed in the two highest treatment groups consisted of great vessel malformations with or without associated ventricular septal defects (VSDs). Urogenital defects were also noted in the 600 mg/kg group. The plasma elimination half-life on GD 8 was 1.0 ± 0.3 hr at 200 mg/kg and 2.3 ± 0.7 hr at 600 mg/kg. Maximal concentrations of total and free drug were 341 ± 18 μg/ml and 181 ± 11 μg/ml, respectively, in the low-dose group and 911 ± 379 μg/ml and 542 ± 224 μg/ml in the high-dose group. No significant changes in any pharmacokinetic parameters (t 1 2, AUC, Cmax, tmax) were observed over the 10-day treatment period at either dose level.

Original languageEnglish (US)
Pages (from-to)485-493
Number of pages9
JournalFundamental and Applied Toxicology
Volume11
Issue number3
DOIs
StatePublished - 1988

Fingerprint

Pharmacokinetics
Valproic Acid
Sprague Dawley Rats
Toxicity
Rats
Defects
Mothers
Teratogens
Fetal Weight
Fetal Growth Retardation
Ventricular Heart Septal Defects
Incidence
Ribs
Skeleton
Anticonvulsants
Area Under Curve
Oral Administration
Half-Life
Spine
Therapeutics

ASJC Scopus subject areas

  • Toxicology

Cite this

Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. / Binkerd, P. E.; Rowland, J. M.; Nau, H.; Hendrickx, Andrew G.

In: Fundamental and Applied Toxicology, Vol. 11, No. 3, 1988, p. 485-493.

Research output: Contribution to journalArticle

Binkerd, P. E. ; Rowland, J. M. ; Nau, H. ; Hendrickx, Andrew G. / Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. In: Fundamental and Applied Toxicology. 1988 ; Vol. 11, No. 3. pp. 485-493.
@article{df9102b2655d49b7b7d8cd500456cba0,
title = "Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats",
abstract = "This study was undertaken to assess the pharmacokinetics and developmental toxicity of the anticonvulsant, valproic acid (VPA), a human teratogen, in Sprague-Dawley rats. Oral administration of 200-800 mg/kg VPA (5-20 × human therapeutic dose) from Gestational Days (GD) 8 to 17 resulted in increasing maternal toxicity at the higher doses with 100{\%} maternal lethality at 800 mg/kg. Although there was an increased incidence of resorptions at 600 mg/kg (48 ± 43{\%}) compared to controls (18 ± 24{\%}), it was not statistically significant. Fetal examination on GD 20 revealed dose-dependent fetal growth retardation (p ≤0.05) as evidenced by decreased fetal weight and length in addition to underossification of both the axial and appendicular skeleton. The incidence of skeletal defects, including abnormal vertebrae, ribs, and craniofacial dysmorphia, also increased with higher doses of VPA. Cardiac anomalies observed in the two highest treatment groups consisted of great vessel malformations with or without associated ventricular septal defects (VSDs). Urogenital defects were also noted in the 600 mg/kg group. The plasma elimination half-life on GD 8 was 1.0 ± 0.3 hr at 200 mg/kg and 2.3 ± 0.7 hr at 600 mg/kg. Maximal concentrations of total and free drug were 341 ± 18 μg/ml and 181 ± 11 μg/ml, respectively, in the low-dose group and 911 ± 379 μg/ml and 542 ± 224 μg/ml in the high-dose group. No significant changes in any pharmacokinetic parameters (t 1 2, AUC, Cmax, tmax) were observed over the 10-day treatment period at either dose level.",
author = "Binkerd, {P. E.} and Rowland, {J. M.} and H. Nau and Hendrickx, {Andrew G}",
year = "1988",
doi = "10.1016/0272-0590(88)90112-1",
language = "English (US)",
volume = "11",
pages = "485--493",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats

AU - Binkerd, P. E.

AU - Rowland, J. M.

AU - Nau, H.

AU - Hendrickx, Andrew G

PY - 1988

Y1 - 1988

N2 - This study was undertaken to assess the pharmacokinetics and developmental toxicity of the anticonvulsant, valproic acid (VPA), a human teratogen, in Sprague-Dawley rats. Oral administration of 200-800 mg/kg VPA (5-20 × human therapeutic dose) from Gestational Days (GD) 8 to 17 resulted in increasing maternal toxicity at the higher doses with 100% maternal lethality at 800 mg/kg. Although there was an increased incidence of resorptions at 600 mg/kg (48 ± 43%) compared to controls (18 ± 24%), it was not statistically significant. Fetal examination on GD 20 revealed dose-dependent fetal growth retardation (p ≤0.05) as evidenced by decreased fetal weight and length in addition to underossification of both the axial and appendicular skeleton. The incidence of skeletal defects, including abnormal vertebrae, ribs, and craniofacial dysmorphia, also increased with higher doses of VPA. Cardiac anomalies observed in the two highest treatment groups consisted of great vessel malformations with or without associated ventricular septal defects (VSDs). Urogenital defects were also noted in the 600 mg/kg group. The plasma elimination half-life on GD 8 was 1.0 ± 0.3 hr at 200 mg/kg and 2.3 ± 0.7 hr at 600 mg/kg. Maximal concentrations of total and free drug were 341 ± 18 μg/ml and 181 ± 11 μg/ml, respectively, in the low-dose group and 911 ± 379 μg/ml and 542 ± 224 μg/ml in the high-dose group. No significant changes in any pharmacokinetic parameters (t 1 2, AUC, Cmax, tmax) were observed over the 10-day treatment period at either dose level.

AB - This study was undertaken to assess the pharmacokinetics and developmental toxicity of the anticonvulsant, valproic acid (VPA), a human teratogen, in Sprague-Dawley rats. Oral administration of 200-800 mg/kg VPA (5-20 × human therapeutic dose) from Gestational Days (GD) 8 to 17 resulted in increasing maternal toxicity at the higher doses with 100% maternal lethality at 800 mg/kg. Although there was an increased incidence of resorptions at 600 mg/kg (48 ± 43%) compared to controls (18 ± 24%), it was not statistically significant. Fetal examination on GD 20 revealed dose-dependent fetal growth retardation (p ≤0.05) as evidenced by decreased fetal weight and length in addition to underossification of both the axial and appendicular skeleton. The incidence of skeletal defects, including abnormal vertebrae, ribs, and craniofacial dysmorphia, also increased with higher doses of VPA. Cardiac anomalies observed in the two highest treatment groups consisted of great vessel malformations with or without associated ventricular septal defects (VSDs). Urogenital defects were also noted in the 600 mg/kg group. The plasma elimination half-life on GD 8 was 1.0 ± 0.3 hr at 200 mg/kg and 2.3 ± 0.7 hr at 600 mg/kg. Maximal concentrations of total and free drug were 341 ± 18 μg/ml and 181 ± 11 μg/ml, respectively, in the low-dose group and 911 ± 379 μg/ml and 542 ± 224 μg/ml in the high-dose group. No significant changes in any pharmacokinetic parameters (t 1 2, AUC, Cmax, tmax) were observed over the 10-day treatment period at either dose level.

UR - http://www.scopus.com/inward/record.url?scp=0023722858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023722858&partnerID=8YFLogxK

U2 - 10.1016/0272-0590(88)90112-1

DO - 10.1016/0272-0590(88)90112-1

M3 - Article

VL - 11

SP - 485

EP - 493

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 3

ER -